


I hereby certify that this correspondence is being
Facsimile transmitted to the United States Patent
and Trademark Office on March 27, 2007.



Frank C. Eisenschenk, Ph.D., Patent Attorney

ELECTION UNDER 35 U.S.C. § 121
Examining Group 1649
Patent Application
Docket No. G-194US03PCT
Serial No. 10/519,335

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Olga N. Chernyshev
Art Unit : 1649
Applicants : Laurent Cavarec, Ilya Chumakov, Benoit Destenaves, Catherine Gonthier, Isabelle Elias
Serial No. : 10/519,335
Filed : December 22, 2004
Conf. No. : 9318
For : Novel KCNQ Polypeptides, Modulators Thereof, and their Uses in the Treatment of Mental Disorders

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

ELECTION UNDER 35 U.S.C. § 121

Sir:

In response to the written Restriction Requirement dated February 27, 2007 in the above-identified patent application, Applicants hereby elect to prosecute the invention of Group I (claims 50-52 and 54-60) and the polypeptide of SEQ ID NO: 2, without traverse.

Prior to examination, Applicants respectfully request that the subject application be amended as follows: